Clinical Trials Logo

Clinical Trial Summary

In this study researchers want to learn more about on the safety of the drug Xarelto. The study will enroll patients for whom the treating doctor are prescribing Xarelto for the prevention of brain attack or the prevention of blockage of an artery in the non-central nervous system. Only patients suffering from decreased renal function and irregular heart beat will be considered. The study plans to include 500 Taiwanese adult male and female patients with the age above 20 years. Patients will be followed up based on routine medical practice over a period of 12 months and information on their well-being and any medical events will collected.


Clinical Trial Description

n/a


Study Design


Related Conditions & MeSH terms


NCT number NCT04356989
Study type Observational
Source Bayer
Contact
Status Completed
Phase
Start date May 13, 2020
Completion date January 16, 2023

See also
  Status Clinical Trial Phase
Completed NCT05022758 - A Study to Learn Whether There Are Differences in the Kidney's Ability to Work Properly in Korean Patients With Non-valvular Atrial Fibrillation (Irregular and Often Rapid Heartbeat Not Caused by a Heart Valve Problem) Treated With Rivaroxaban as Compared to Those Treated With Warfarin
Active, not recruiting NCT03887780 - A Study to Evaluate the Safety and Effectiveness of Rivaroxaban (Xarelto) for Prevention of Stroke and Systemic Embolism in Indian Patients With Non-valvular Atrial Fibrillation (NVAF)
Completed NCT02954237 - AMPLATZERâ„¢ Cardiac Plug Observational Post-Approval Study
Completed NCT01598051 - Xarelto [SPAF-QOL] Post-marketing Surveillance in Japan
Recruiting NCT05232643 - A Study Evaluating the Associations Between Clinical Characteristics and Use of Oral Anticoagulants in Italian Elderly Participants With Non-Valvular Atrial Fibrillation
Recruiting NCT03234114 - Optimal Antithrombotic Therapy for ACS Patients Concomitant With AF and Implanted With New-generation DES (OPTIMA-3, 4) Phase 4
Completed NCT03746301 - Xarelto on Prevention of Stroke and Non-Central Nervous Systemic Embolism in Renally Impaired Korean Patients With Non-valvular Atrial Fibrillation
Completed NCT02663076 - Factor XA - Inhibition in RENal Patients With Non-valvular Atrial Fibrillation - Observational Registry
Withdrawn NCT02153424 - Early Post-marketing Study of Eliquis (Apixaban) N/A
Completed NCT05027061 - A Study of Participants With Non-Valvular Atrial Fibrillation (NVAF) Treated or Untreated With Oral Anticoagulant in the National Cerebral and Cardiovascular Center (NCVC) in Japan